Diffuse Worsening Pain on High-Dose Opioid: Hyperalgesia or Progression?
Ms. S is a 52-year-old woman with chronic abdominal pain from idiopathic pancreatitis. Over 8 months her morphine equivalent daily dose has risen from 60 mg to 180 mg because of worsening diffuse pain. She now describes burning pain in both arms and legs, allodynia to bedsheets, and pain that is worse after each opioid dose. She has no new abdominal findings; lipase and imaging are unchanged. She reports anxiety and poor sleep. On examination, she has diffuse hyperalgesia and no focal neurologic deficit. Her primary care physician suggests increasing the opioid again because 'the dose is not working.'
1. Differentiate opioid tolerance, opioid-induced hyperalgesia, and progression of her underlying disease using the clinical features.
Read the worked answer
Tolerance means the same dose produces less effect over time, but pain usually remains in the original distribution and responds temporarily to a higher dose. Opioid-induced hyperalgesia is a paradoxical state of increased pain sensitivity, often diffuse, with allodynia and hyperalgesia beyond the original pain site; pain may worsen as the dose rises. Progression of pancreatitis would usually produce more localized abdominal pain, possibly with vomiting, weight loss, elevated lipase, or new imaging findings. Her pain has spread to both arms and legs, she has diffuse hyperalgesia and bedsheet allodynia, and imaging and lipase are unchanged. That pattern favors opioid-induced hyperalgesia or central sensitization, not simple tolerance or disease progression. However, this is a clinical diagnosis of exclusion; anxiety and poor sleep can amplify pain and must be addressed.
2. What mechanistic explanation links opioid exposure to hyperalgesia, and how does it guide management?
Read the worked answer
Repeated opioid exposure can sensitize central pain pathways through NMDA receptor activation, descending facilitation, glial activation, and changes in endogenous opioid systems. The result is a shift toward pain facilitation rather than analgesia. This explains why escalating the dose may worsen diffuse pain and allodynia. Management is therefore not another dose increase. Reduce the opioid dose gradually, add non-opioid multimodal therapy, and treat anxiety and sleep. Ketamine or other NMDA antagonists are sometimes used for severe refractory cases, but evidence is limited and monitoring is required. Opioid rotation is not a guaranteed fix because cross-tolerance and hyperalgesia can persist. The key is to recognize the paradox, set realistic goals, and avoid chasing the pain with escalating opioids.
3. Design a tapering and monitoring plan, including safety and patient communication.
Read the worked answer
Explain that the opioid may now be amplifying her pain rather than relieving it, and that the goal is function and safety, not a perfect pain score. Because she is on 180 mg morphine equivalents, taper slowly, for example by 5% to 10% every 2 to 4 weeks, with slower steps if withdrawal or distress occurs. Do not stop abruptly. Monitor pain distribution, function, sleep, withdrawal symptoms, mood, and suicidal ideation. Prescribe naloxone and involve behavioral health. Add physical therapy, sleep treatment, and non-opioid adjuvants such as duloxetine or gabapentinoid if appropriate. If severe withdrawal or instability develops, use an inpatient or structured outpatient setting. Document the rationale and give clear follow-up. If pain worsens focally with new abdominal signs, reassess for pancreatitis progression rather than assuming hyperalgesia.